RTTNews BiotechCodex · 实盘不做把握 7/10
北京时间·🕒 发布 13:44:26时区推断·⟳ 抓取 13:45:26·⚡ 决策 07-15 13:52:30 +7m04s·104.1 天前
罗氏Gazyva/Gazyvaro治疗pMN补充申请获FDA优先审评
FDA优先审评提升Gazyva/Gazyvaro新增适应症获批概率和时间确定性，但这不是最终批准。
📄 原文RTTNews Biotech↗ 原文
Roche (RHHBY) announced that the FDA has granted Priority Review to the company's supplemental Biologics License Applic…
不做 Roche Holding（RHHBY.US）
优先审评不是最终批准，且罗氏体量太大、未披露新增销售量级，缺少市值级真实增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-15 · 扩散 medium · price-in 风险 low ↗
消息传播链
- 报道FDA授予Gazyva/Gazyvaro治疗原发性膜性肾病补充申请优先审评。
关键理由
- FDA优先审评提升Gazyva/Gazyvaro新增适应症获批概率和时间确定性，但这不是最终批准。
- Gazyva是罗氏既有商业化产品，pMN新增适应症相对罗氏集团收入和市值大概率太小；现有销售基数和新增患者渗透率未显示市值级增量。
主要风险
- 若后续FDA正式批准并披露显著患者池、定价或指南替代优势，可重新评估。
工具调用 · 历史记录,结果未知(1 种)
- stock_quote · 结果未知
原文全文
展开原文 · 1,134 字
Roche (RHHBY) announced that the FDA has granted Priority Review to the company's supplemental Biologics License Application for Gazyva/Gazyvaro for the treatment of primary membranous nephropathy. The priority review is based on the positive phase III MAJESTY results.
The FDA has already granted Breakthrough Therapy Designation to Gazyva/Gazyvaro in pMN. The company noted that this is is the second indication in recent months for which the FDA has granted priority review to Gazyva/Gazyvaro, following idiopathic nephrotic syndrome in May 2026.
At last close, Roche shares were trading at 327.00 Swiss francs, down 1.12%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
The FDA has already granted Breakthrough Therapy Designation to Gazyva/Gazyvaro in pMN. The company noted that this is is the second indication in recent months for which the FDA has granted priority review to Gazyva/Gazyvaro, following idiopathic nephrotic syndrome in May 2026.
At last close, Roche shares were trading at 327.00 Swiss francs, down 1.12%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
July 13, 2026 10:12 ET The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。